Dr. Simos Simeonidis is Co-Founder and Managing Partner of Kos Biotechnology Partners, an investment firm which invests in the biopharmaceutical space. He is also the Co-Founder, Chairman of the Board and interim CEO of Delsona Therapeutics, a healthcare company spun out of Columbia University, that uses Focused Ultrasound to open the blood-brain barrier to deliver therapeutics into the CNS, with applications in neurological disorders (Alzheimer's, Parkinson's, ALS etc) and oncology (Glioblastoma Multiforme, DIPG etc)
Dr. Simeonidis's career in biotechnology spans more than 25 years. The first chapter of his career started out in academia, as a molecular geneticist dissecting mechanisms of disease (Columbia and Harvard Medical Schools), before transitioning into the business side of biotech and pharma through an MBA in Healthcare Management, followed by industry experience at Novartis, Johnson & Johnson and GlaxoSmithKline. Next, Dr. Simeonidis then spent more than a decade as a Senior Analyst and Managing Director covering the biotechnology space for several investment banks (Morgan Stanley, Cowen, RBC), as a senior executive and board member in a number of biopharma companies (Novartis, Regulus, Sarissa Capital Acquisition Corp., Delsona Therapeutics) and finally as a biotechnology investor (Sarissa Capital Management, Ally Bridge Group) before founding Kos Biotechnology Partners.
Dr. Simeonidis received his B.S. degree in Biology from Loyola University Chicago, and his M.A., M.Phil. and Ph.D. degrees in Cellular, Molecular and Biophysical Sciences from Columbia University’s College of Physicians & Surgeons. He completed his Postdoctoral Fellowship at the laboratory of Professor Tucker Collins at Harvard Medical School and the Brigham and Women’s Hospital, where he worked on the transcriptional regulation of gene expression via the NF-kappaB/IkappaB pathway. Dr. Simeonidis also holds an MBA in Healthcare Management from the Wharton School of the University of Pennsylvania.
